Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.61 |
| ▸ | CYP4A11 | Q02928 | 2/20 | 0.56 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.54 |
| ▸ | CXCR1 | P25024 | 3/20 | 0.54 |
| ▸ | CXCR2 | P25025 | 3/20 | 0.54 |
| ▸ | CA1 | P00915 | 2/20 | 0.53 |
| ▸ | CA2 | P00918 | 2/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.53 |
| ▸ | CA12 | O43570 | 1/20 | 0.53 |
| ▸ | CA7 | P43166 | 1/20 | 0.53 |
| ▸ | CA9 | Q16790 | 1/20 | 0.53 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 2/20 | 0.53 |
| ▸ | PTGS1 | P23219 | 3/20 | 0.50 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.50 |
| ▸ | TSHR | P16473 | 2/20 | 0.50 |
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.50 |
| ▸ | AKR1C3 | P42330 | 2/20 | 0.50 |
| ▸ | ALB | P02768 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25146751 | 0.95 | LOXL2 (0.56) | LOXL2CYP4A11CYP4F2CXCR1CXCR2 | |
| SCHEMBL8121457 | 0.90 | PTPN1 (0.55) | LOXL2CYP4A11CYP4F2CXCR1CXCR2 | |
| SCHEMBL13638915 | 0.87 | RAB9A (0.68) | MAPTTSHRLMNAMEN1KMT2A | |
| SCHEMBL9372952 | 0.87 | RAB9A (0.68) | MAPTTSHRLMNAMEN1KMT2A | |
| SCHEMBL5177723 | 0.87 | LOXL2 (0.59) | LOXL2CYP4A11CYP4F2CA1CA2 | |
| SCHEMBL28403117 | 0.86 | PTGS1 (0.52) | CYP4A11CYP4F2CXCR1CXCR2PTGS1 | |
| SCHEMBL2658692 | 0.86 | PTGS1 (0.60) | LOXL2CYP4A11CXCR1CXCR2MAPT | |
| SCHEMBL2331067 | 0.85 | LOXL2 (0.58) | LOXL2CYP4A11CYP4F2CA1CA2 | |
| SCHEMBL10662499 | 0.85 | LOXL2 (0.68) | LOXL2CYP4A11CYP4F2CA1CA2 | |
| SCHEMBL3026218 | 0.85 | LOXL2 (0.58) | LOXL2CYP4A11CYP4F2CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 123 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-1997034860-A1 | A PROCESS FOR THE PREPARATION OF α-ARYLPROPIONIC ACIDS AND THE INTERMEDIATES THEREOF | CONSIGLIO NAZIONALE DELLE RICERCHE (IT) | 1997-09-25 | — | — | WO | claimed |
| US-11827640-B2 | Substituted pyrazolo[1,5-a]pyrimidines as CFTR modulators | ILDONG PHARMACEUTICAL CO., LTD. (KR) | 2023-11-28 | — | — | US | disclosed |
| US-11827640-B2 | Substituted pyrazolo[1,5-a]pyrimidines as CFTR modulators | ILDONG PHARMACEUTICAL CO., LTD. (KR) | 2023-11-28 | — | — | US | disclosed |
| US-20230365568-A1 | PLK1 POLO BOX DOMAIN INHIBITORS AND METHOD OF TREATING CANCER | THE UNITED STATES OF AMERICA,AS REPRESENTED BY THE SECRETARY,DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2023-11-16 | — | — | US | disclosed |
| US-11684609-B2 | Compounds and methods for treating an epileptic disorder | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-06-27 | — | — | US | disclosed |
| US-20230002335-A1 | SMALL MOLECULE ENHANCEMENT OF 20S PROTEASOME ACTIVITY TARGETS INTRINSICALLY DISORDERED PROTEINS | BOARD OF TRUSTEES OF MICHIGAN STATE UNIVERSITY | 2023-01-05 | — | — | US | disclosed |
| US-11358942-B2 | Substituted phenothiazines as proteasome activators | BOARD OF TRUSTEES OF MICHIGAN STATE UNIVERSITY (US) | 2022-06-14 | — | — | US | disclosed |
| US-20210323913-A1 | SIGMA RECEPTOR BINDERS | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2021-10-21 | — | — | US | disclosed |
| US-20210300903-A1 | SIGMA RECEPTOR BINDERS | UNIV TEXAS (US) | 2021-09-30 | — | — | US | disclosed |
| US-20200165216-A1 | SMALL MOLECULE PROTEASOME ACTIVATORS AND USES THEREOF | BOARD OF TRUSTEES OF MICHIGAN STATE UNIVERSITY | 2020-05-28 | — | — | US | disclosed |
| US-7229972-B2 | Semisynthetic trimethylenedioxy-erythromycin derivatives and their use in treating bacterial infections and cystic fibrosis; preparation | ENANTA PHARMACEUTICALS, INC. (US) | 2007-06-12 | — | — | US | disclosed |
| WO-2007062314-A2 | HETEROCYCLIC CETP INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-05-31 | — | — | WO | disclosed |
| WO-2007062342-A1 | HETEROCYCLIC CETP INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-05-31 | — | — | WO | disclosed |
| US-20070117797-A1 | Alkylamino, arylamino, and sulfonamido cyclopentyl amide modulators of chemokine receptor activity | MERCK SHARP & DOHME CORP. | 2007-05-24 | — | — | US | disclosed |
| US-20070082853-A1 | 6, 11-bridged tricyclic macrolides | ENANTA PHARMACEUTICAL, INC. | 2007-04-12 | — | — | US | disclosed |
| US-7189704-B2 | 6-11 bicyclic ketolide derivatives | ENANTA PHARMACEUTICALS, INC. (US) | 2007-03-13 | — | — | US | disclosed |
| US-7189704-B2 | 6-11 bicyclic ketolide derivatives | ENANTA PHARMACEUTICALS, INC. (US) | 2007-03-13 | — | — | US | disclosed |
| EP-0760359-B1 | Method for preparing aromatic carbonate | MITSUBISHI GAS CHEMICAL CO (JP) | 1999-10-20 | — | — | EP | disclosed |
| US-5714627-A | REACTING A DIALKYL CARBONATE WITH AN AROMATIC CARBOXYLIC ACID ARYL ESTER IN THE PRESENCE OF A CATALYST | MITSUBISHI GAS CHEMICAL COMPANY, INC. (JP) | 1998-02-03 | — | — | US | disclosed |
| EP-0760359-A1 | Method for preparing aromatic carbonate | MITSUBISHI GAS CHEMICAL COMPANY, INC. (JP) | 1997-03-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070117797-A1 | Alkylamino, arylamino, and sulfonamido cyclopentyl amide modulators of chemokine receptor activity | CCR7, ACKR3, CCR2 | LOXL2 1979/4885CYP4A11 684/4885CYP4F2 3304/4885 |
| US-11827640-B2 | Substituted pyrazolo[1,5-a]pyrimidines as CFTR modulators | PDE4A, PDE4B, PDE5A | LOXL2 3971/4885CYP4A11 187/4885CYP4F2 1510/4885 |
| US-11358942-B2 | Substituted phenothiazines as proteasome activators | PSMG3, ADRM1, PSME3 | LOXL2 2727/4885CYP4A11 4190/4885CYP4F2 3879/4885 |
| US-20210323913-A1 | SIGMA RECEPTOR BINDERS | SIGMAR1, OPRK1, OPRL1 | LOXL2 3075/4885CYP4A11 3269/4885CYP4F2 3847/4885 |
| US-20070082853-A1 | 6, 11-bridged tricyclic macrolides | CYP2B6, CYP2D6, ABCB11 | LOXL2 4754/4885CYP4A11 17/4885CYP4F2 259/4885 |
| US-20230002335-A1 | SMALL MOLECULE ENHANCEMENT OF 20S PROTEASOME ACTIVITY TARGETS INTRINSICALLY DISORDERED PROTEINS | PSMG3, PSME3, PSME1 | LOXL2 3380/4885CYP4A11 4341/4885CYP4F2 4358/4885 |
| US-20200165216-A1 | SMALL MOLECULE PROTEASOME ACTIVATORS AND USES THEREOF | PSMG3, PSME3, PSMB2 | LOXL2 2846/4885CYP4A11 4521/4885CYP4F2 4596/4885 |
| US-20230365568-A1 | PLK1 POLO BOX DOMAIN INHIBITORS AND METHOD OF TREATING CANCER | PLK1, PLK4, BUB1B | LOXL2 2311/4885CYP4A11 4177/4885CYP4F2 4525/4885 |
| US-11684609-B2 | Compounds and methods for treating an epileptic disorder | GABRE, SLC6A1, GABBR1 | LOXL2 671/4885CYP4A11 305/4885CYP4F2 433/4885 |
| US-20210300903-A1 | SIGMA RECEPTOR BINDERS | SIGMAR1, OPRK1, OPRL1 | LOXL2 3192/4885CYP4A11 3291/4885CYP4F2 3855/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.